|
|
|
|
|
Vesanoid: profile and news
Other information Indication For topical treatment of cutaneous lesions in patients with AIDS- related Kaposi sarcomaia. Pharmacology Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid indicated for topical treatment of cutaneous lesions in patients with AIDS- related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Mechanism Of Action Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. Drug Category Antineoplastic Agents; ATC:L01XX22 Brand Names/Synonyms Alitretinoin; Alitretinoin [Usan]; Avita; Beta-Retinoic Acid; Panretin; Panretin Gel; Panretyn; Panrexin; Renova; Retin-A; Retin-a Micro; Retinoate; Retinoic Acid; Trans-Retinoic Acid; Tretin M; Tretinoin; Vesanoid; Vitamin a Acid Dosage Forms Not Available Absorption Not Available Interactions Interactions for Alitretinoin: Patients who are applying Panretin® gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products. Animal toxicology studies showed increased DEET toxicity when DEET was included as proof of the formulation. Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including protease inhibitors, macrolide antibiotics, and azole antifungals, the effect of Panretin® gel on the steady-state concentrations of these drugs is not known. No drug interaction data are available on concomitant administration of Panretin® gel and systemic anti-KS agents. Chemical IUPAC Name 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-nona-2,4,6,8-tetraenoicacid Chemical Formula C20H28O2 Half Life Not Available Drug Type Approved Drug # Accession No APRD00017 CAS Registry Number 3/8/5300 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |